Krilogy Financial’s Editas Medicine EDIT Stock Holding History

Krilogy Financial’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200	Closed	-$3K	–	813
2017 Q2	$3K	Buy	+200	New	+$3.6K	﹤0.01%	636

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PVMCV

Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Krilogy Financial's EDIT Position: Q3 2017 in Review

Krilogy Financial sold out of Editas Medicine (EDIT) in Q3 2017, closing a stake of 200 shares — an estimated $3K sold.

Krilogy Financial first reported a position in EDIT in Q2 2017 and held it in 1 quarter. The position peaked at $3K in Q2 2017. 116 funds tracked by Wall St. Rank hold EDIT as of Q3 2017.

Krilogy Financial reported no remaining Editas Medicine position as of Q3 2017 after selling out during the quarter.
Krilogy Financial sold 200 Editas Medicine shares in Q3 2017, an estimated $3K.
Krilogy Financial first reported a position in Editas Medicine in Q2 2017 and held it in 1 quarter.
Krilogy Financial's Editas Medicine position peaked at $3K in Q2 2017.
116 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2017.

Based on Krilogy Financial's 13F filing for Q3 2017, filed 15 Nov 2017.